Liminal BioSciences (LMNL) Reports Q3 Revenues of $600K
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Liminal BioSciences Reports Third Quarter Financial Results
November 12, 2020 4:57 PM ESTPDUFA Target Action Date of June 5, 2021 for Ryplazim® (plasminogen) BLA Submission Ryplazim® (plasminogen) Abstracts Selected for Presentation at American Society of Hematology (ASH) in early December Changes to Board of Directors OXER1 Antagonist Preclinical R&D Program Acquired New Appointments to Board of Directors US$30 MM in gross proceeds from a private placement closed in November C$29.1 MM in proceeds from long-term loan from SALP in September Executive team changes
LAVAL, QC, and CAMBRIDGE, England, Nov. 12, 2020 /PRNewswire/ -... More
